Omega-3 Fatty Acids and Cardiac Arrhythmias: Prior Studies and Recommendations for Future Research

London, Barry; Chen, Albert; Anderson, Mark E.; Giles, Wayne R.; Wagoner, David R. Van; Balk, Ethan M; Billman, George E.; Chung, Mei; Lands, William E.M.; Leaf, Alexander; McAnulty, John H.; Martens, Jeffrey R.; Costello, Rebecca B.; Lathrop, David A.

doi:10.1161/circulationaha.107.712984

Cited by 153 publications

(74 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among several ongoing or planned large-scale randomized studies in Europe on the effect of n-3 PUFA on different cardiovascular end-points, 28 only the Omega trial has been designed to examine the effect of 1 g/day n-3 PUFA versus placebo on sudden cardiac death as the primary end-point in 3800 patients with a recent myocardial infarction. In the GISSI-Heart Failure, randomizing almost 7000 patients with class II-IV heart failure to n-3 PUFA, rosuvastatin, both active drugs or placebo (double-blind 2x2 factorial design), the primary end-point is all-cause mortality or hospital admissions for cardiovascular reasons.…”

Section: Future and Ongoing Randomized Trials With Cardiovascular Endmentioning

confidence: 99%

n-3 fatty acids and cardiovascular disease

Grundt¹,

Nilsen²

2008

Haematologica

View full text Add to dashboard Cite

Section: Future and Ongoing Randomized Trials With Cardiovascular Endmentioning

confidence: 99%

n-3 fatty acids and cardiovascular disease

Grundt¹,

Nilsen²

2008

Haematologica

View full text Add to dashboard Cite

“…The study found that increased ALA intake might decrease the risk of CVD 44 . Studies of dietary n-3 levels have found that these compounds reduce vulnerability to arrhythmia by stabilizing the myocardial membrane 45,46 . These findings corroborate the inverse relationship between the dietary intake of EPA and DHA from fish and the risk of sudden heart-related death reported in both case-control and cohort studies 47,48 .…”

Section: Fatty Acids and Cardiovascular Diseasementioning

confidence: 99%

Dietary Fatty Acids and Cardiovascular Disease: A review

Prates¹,

Frankenberg²,

Rodrigues³

2015

cbr

View full text Add to dashboard Cite

Fatty acids (FAs) can be classified into saturated (SFA), unsaturated (poly-or monounsaturated) and trans FA. Recent studies have found that both the quantity and quality of dietary FAs may influence their role in metabolic pathways. Due to their chemical composition, some FAs play a major role in the development and progression of cardiovascular disease. This is especially true for SFA and n-3 polyunsaturated fatty acids, which include marine eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The proinflammatory effects of high SFA intake may increase the risk of atherosclerosis. On the other hand, dietary n-3 intake may reduce the risk of cardiovascular disease by decreasing atherosclerosis, inflammation, and thrombotic processes. The goal of this study was to review the current literature on the role of FA intake in the prevention and risk of cardiovascular disease. Keywords: Fatty acids; cardiovascular disease ARTICLE SUMMARYStrengths: The few studies linking diet and the consumption of fatty acids to cardiovascular disease increase the strength of this research. Limitations of this study: Literature review study with cross-sectional design.

show abstract

“…Similarly, foods rich in longchain n-3 PUFA (e.g. nuts or fish such as herring, tuna, sardines and wild salmon), which can limit sudden death from cardiac arrhythmia, may not be readily accessible to lower socio-economic groups (28) .…”

Section: Social Inequalities and Saltmentioning

confidence: 99%

Review ArticleCurrent salt reduction policies across gradients of inequality-adjusted human development in the WHO European region: minding the gaps

Rodríguez-Fernández

Siopa

Simpson

et al. 2013

Public Health Nutr.

View full text Add to dashboard Cite

Objective: To assess current salty reduction policies in countries of the WHO European Region against the backdrop of varying levels of human development adjusted for income, education and health (longevity) inequalities. Design: Population-based, cross-sectional study, with data gathered through systematic review of relevant databases and supplementary information provided by WHO Nutrition Counterparts. Setting: Member States of the WHO European Region. Subjects: Inequality-adjusted Human Development Index scores were analysed against assessed levels of development and implementation of national nutrition policies and initiatives targeting population-level salt reduction. Results: Within the WHO European Region, Inequality-adjusted Human Development Index values among countries with no existing salt reduction initiatives (mean 0?643 (SE 0?022)) were significantly lower than among those with either partially implemented/planned salt initiatives (mean 0?766 (SE 0?017), P , 0?001) or fully implemented salt initiatives (mean 0?780 (SE 0?021), P , 0?001). Conclusions: Where salt reduction strategies are implemented as an integral part of national policy, outcomes have been promising. However, low-and middle-income countries may face severe resource constraints that keep them from emulating more comprehensive strategies pursued in high-income countries. Care must be taken to ensure that gaps are not inadvertently widened by monitoring differential policy impacts of salt policies, particularly regarding trade flows.

show abstract

Omega-3 Fatty Acids and Cardiac Arrhythmias: Prior Studies and Recommendations for Future Research

Cited by 153 publications

References 165 publications

n-3 fatty acids and cardiovascular disease

n-3 fatty acids and cardiovascular disease

Dietary Fatty Acids and Cardiovascular Disease: A review

Review ArticleCurrent salt reduction policies across gradients of inequality-adjusted human development in the WHO European region: minding the gaps

Contact Info

Product

Resources

About